New hope for HIV patients with Hard-to-Treat hepatitis c
NCT ID NCT00901524
First seen Apr 28, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tested a stronger combination of two hepatitis C drugs (PegIFN-alpha2a and Ribavirin) in 58 adults with both HIV and hepatitis C (genotypes 1 or 4) who had not responded to previous treatment. The goal was to see if the optimized dose could clear the hepatitis C virus for at least six months after stopping therapy. The approach involved an initial 6-month treatment phase, with possible extension based on early response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Tenon Service des Maladies Infectieuses
Paris, 75970, France
Conditions
Explore the condition pages connected to this study.